Table 3.
Relative area-under-the-drug dissolution curve for the selection of suitable ternary components (i.e., secondary polymers).
| Sample | Percent Rel. AUDCTotal (Relative to Lot 5 KSD) | Percent Rel. AUDC0.01 N HCl (Relative to Lot 5 KSD) | Percent Rel. AUDCFaSSIF (Relative to Lot 5 KSD) |
|---|---|---|---|
| Lot 5 KSD | 100.0 | 100.0 | 100.0 |
| Abiraterone API | 8.4 | 1.8 | 46.2 |
| Generic Abiraterone Acetate Tablet |
18.4 | 3.6 | 104.1 |
| Lot 5 KSD with HPMC E15 | 89.0 | 83.1 | 109.1 |
| Lot 5 KSD with HPMC E50 | 89.2 | 82.1 | 113.8 |
| Lot 5 KSD with PVP K90 | 91.8 | 87.9 | 105.0 |
| Lot 5 KSD with HPMCAS 126 G | 108.9 | 83.5 | 244.8 |
| Lot 5 KSD with HPMCAS 716 G | 85.9 | 86.1 | 77.4 |
| Lot 5 KSD with HPMCAS 912G | 88.1 | 79.7 | 134.6 |
| Lot 5 KSD with Na CMC | 85.4 | 85.8 | 79.1 |
| Lot 5 KSD with PVAP | 80.4 | 78.0 | 85.3 |
| Lot 5 KSD with Eudragit L-100 55 | 93.8 | 90.3 | 107.5 |